REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

16/04/2020 14:25

RNS Number : 9257J
  
GlaxoSmithKline PLC
  
16 April 2020
  
 

GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms E Walmsley




b)


Position/status


Chief Executive Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.4420


970


 




 


£15.4420


965


 




 


£15.4420


777


 




 


 


 


 




d)


Aggregated information
 


2,712




 
Aggregated volume Price


 
£15.4420




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Dr H Barron




b)


Position/status


Chief Scientific Officer and President, R&D




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 April 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$38.8800


559


 




 


$38.8800


439


 




 


 


 


 




d)


Aggregated information
 


998




 
Aggregated volume Price


 
$38.8800




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Connor     
 




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.4420


205


 




 


£15.4420


253


 




 


£15.4420


245


 




 


 


 


 




d)


Aggregated information
 


703




 
Aggregated volume Price


 
£15.4420




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Conrad




b)


Position/status


SVP Human Resources




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.4420


101


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


Senior Vice President and General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.4420


144


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


Senior Vice President and General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 April 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$38.8800


48


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics & Compliance




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.4420


107


 




 


£15.4420


106


 




 


£15.4420


76


 




 


 


 


 




d)


Aggregated information
 


289




 
Aggregated volume Price


 
£15.4420




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms S Jackson




b)


Position/status


SVP, Global Communications & CEO Office




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.4420


61


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
£15.4420




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr I Mackay




b)


Position/status


Chief Financial Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.4420


524


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
£15.4420




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr B McNamara




b)


Position/status


CEO, GSK Consumer Healthcare




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 April 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$38.8800


100


 




 


$38.8800


94


 




 


$38.8800


80


 




 


 


 


 




 


 


 


 




d)


Aggregated information
 


274




 
Aggregated volume Price


 
$38.8800




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.4420


195


 




 


£15.4420


269


 




 


£15.4420


235


 




 


 


 


 




d)


Aggregated information
 


699




 
Aggregated volume Price


 
£15.4420




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.4420


199


 




 


£15.4420


239


 




 


£15.4420


172


 




 


 


 


 




d)


Aggregated information
 


610




 
Aggregated volume Price


 
£15.4420




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Simard




b)


Position/status


President, Pharmaceuticals Supply Chain




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.4420


86


 




 


£15.4420


122


 




 


 


 


 




d)


Aggregated information
 


208




 
Aggregated volume Price


 
£15.4420




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms K Terrell




b)


Position/status


Chief Digital & Technology Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 April 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$38.8800


33


 




 


$38.8800


119


 




 


$38.8800


82


 




 


 


 


 




d)


Aggregated information
 


234




 
Aggregated volume Price


 
$38.8800




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.4420


134


 




 


£15.4420


140


 




 


£15.4420


99


 




 


 


 


 




d)


Aggregated information
 
 


373




Aggregated volume Price


£15.4420




e)


Date of the transaction


2020-04-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHXQLFFBZLFBBK